Roth Capital Reiterates Buy On Curis Shares, $10 PT
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Curis Inc. (NASDAQ:CRIS) with a price target of $10.00.
Pantginis noted, “Roche announced 3Q14 Erivedge revenue of $35.0 million, which was essentially flat from 2Q14 revenue of $36.6 million. While we had expected quarter-over-quarter growth, we believe there is still significant room for Erivedge revenue growth going forward based on Roche’s commitment to expanding both geographies and indications. We believe CRIS is successfully progressing internal programs towards data catalysts in 2015.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -14.2% and a 28.6% success rate. Pantginis has a -8.4% average return when recommending CRIS, and is ranked #3329 out of 3335 analysts.